The company's shares have been traded in the General Standard on the Regulated Market at Frankfurt Stock Exchange up to now. They are to be admitted to the part of the Regulated Market at Frankfurt Stock Exchange in which additional requirements have to be met (Prime Standard). The application relates to all 9 803 348 ordinary bearer shares with no par value.
Following the switch to the Prime Standard, Mologen AG will be listed in the stock market segment in which Deutsche Börse makes the highest transparency and disclosure requirements. Listing in the Prime Standard is also essential for inclusion in one of Deutsche Börse's specialised indices.
Dr Matthias Schroff, Chairman of the Executive Board of Mologen AG: "Our aims in switching to the Prime Standard are to increase share liquidity and to make the share more attractive to investors because of the increase in transparency, in order to broaden our shareholder base. This step is in addition the logical response to the positive interest in the Mologen share shown by the capital market."
About Mologen
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures. Activities focus on product developments for the treatment of cancer and vaccines for serious infections. MOLOGEN was founded in 1998 and is among the few biotechnology companies in the world with well-tolerated, DNA-based cancer treatment in the clinical development stage. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200).
